U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07082751) titled 'Prognostic Model for MASLD Related Cirrhosis' on June 07.
Brief Summary: This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months. The primary endpoint was cumulative incidence of liver-related events (including decompensation events, hepatocellular carcinoma, liver transplantation, and liver-related mortality) and all-cause mortality. Secondary endpoints included cumulative incidence of metabolic events and changes in non-invasive fibrosis markers.
Study Start Date: Aug. 13
Study Type: OBSERVATIONAL
Condition:
Metabolic Dysfunction ...